A probe for co-diagnosis and treatment monitoring, preparation method and application thereof

By preparing FTBGd nanoprobes and integrating multimodal imaging with statins, the insufficient sensitivity of early atherosclerotic lesion detection and the targeting issues of imaging agents within plaques were resolved, enabling precise diagnosis and treatment monitoring, and improving the accuracy and effectiveness of atherosclerosis management.

CN120960464BActive Publication Date: 2026-03-03NANKAI UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-10-20
Publication Date
2026-03-03

AI Technical Summary

Technical Problem

Existing diagnostic methods lack sensitivity and specificity in detecting early atherosclerotic lesions. Traditional imaging agents have low accumulation efficiency within plaques, difficulty in penetrating to the plaque core, and poor targeting of foam cells, which affects imaging results and may cause side effects.

Method used

Using FTBGd as the core component, combined with statin drugs, and utilizing phospholipid compounds and poly(p-phenylacetone ethoxylate) as carriers, nanoprobes were prepared, integrating MRI, near-infrared II region (FLI), and PAI imaging modes, and surface-modified macrophage membranes to achieve multimodal imaging and treatment monitoring.

Benefits of technology

It enables precise multimodal imaging of atherosclerosis, prolongs in vivo circulation time, enhances targeted aggregation, reduces CD47 expression in foam cells, promotes targeted release of active drug components, inhibits plaque progression, and improves diagnostic accuracy and treatment efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120960464B_ABST
    Figure CN120960464B_ABST
Patent Text Reader

Abstract

This invention relates to the field of biomedical technology, and more particularly to a probe for synergistic diagnosis and treatment monitoring, its preparation method, and its application. The probe is a lipid nanoparticle, co-assembled with FTBGd and statins as a hydrophobic core, and biocompatible phospholipid compounds and poly(p-phenylacetone) thioglycol as carriers. The probe provided by this invention can reduce the risk of phagocytosis by monocytes, prolong their circulation time in the body, and enhance the targeted aggregation of inflammatory endothelium in atherosclerosis; it can achieve multimodal imaging of foam cells, enabling early identification and multidimensional information acquisition of atherosclerosis; it can reduce the expression of CD47 on the surface of foam cells, enhance the phagocytic activity of macrophages, and inhibit the progression of necrotic cores and plaques. The preparation method provided by this invention has mild reaction conditions, is simple to operate, and is conducive to large-scale production.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Nano-probe for dual-targeting atherosclerotic plaque as well as preparation method and application of nano-probe

    CN117731634A

  • Nano diagnosis and treatment preparation for multi-mode imaging and cancer combined immunotherapy and preparation method of nano diagnosis and treatment preparation

    CN118490849A